Royal Bank Of Canada Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines (NASDAQ:RVMD) had its price objective lifted by stock analysts at Royal Bank Of Canada from $260.00 to $321.00 in a report issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada‘s target price indicates a potential upside of 66.94% from the company’s previous close.

RVMD has been the subject of several other research reports. Stifel Nicolaus increased their target price on Revolution Medicines from $215.00 to $230.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Wolfe Research restated an “outperform” rating and set a $220.00 price target on shares of Revolution Medicines in a research report on Monday, August 10th. Oppenheimer upped their price target on Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. HC Wainwright increased their price objective on Revolution Medicines from $195.00 to $280.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Finally, Sanford C. Bernstein increased their price objective on Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $263.15.

Revolution Medicines Price Performance

RVMD traded up $14.63 during trading on Thursday, reaching $192.28. 4,496,326 shares of the company were exchanged, compared to its average volume of 1,940,895. The company’s 50-day moving average is $196.88 and its two-hundred day moving average is $157.56. Revolution Medicines has a 12-month low of $58.91 and a 12-month high of $224.31. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The company has a market cap of $41.21 billion, a price-to-earnings ratio of -21.11 and a beta of 1.44.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The business had revenue of $197.56 million during the quarter, compared to the consensus estimate of $25.58 million. During the same quarter in the previous year, the firm posted ($1.61) earnings per share. Research analysts forecast that Revolution Medicines will post -8.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, Director Elizabeth M. Anderson sold 10,143 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the completion of the sale, the director directly owned 4,333 shares in the company, valued at $836,442.32. The trade was a 70.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark A. Goldsmith sold 80,000 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the sale, the insider directly owned 267,330 shares of the company’s stock, valued at approximately $55,925,436. This represents a 23.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 290,991 shares of company stock worth $59,422,765. 7.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Revolution Medicines

A number of hedge funds have recently modified their holdings of RVMD. Bluestem Financial Advisors LLC increased its stake in Revolution Medicines by 4.8% in the 3rd quarter. Bluestem Financial Advisors LLC now owns 1,256 shares of the company’s stock worth $258,000 after buying an additional 58 shares in the last quarter. IFP Advisors Inc raised its holdings in Revolution Medicines by 8.7% during the third quarter. IFP Advisors Inc now owns 810 shares of the company’s stock valued at $166,000 after acquiring an additional 65 shares during the period. Brighton Jones LLC lifted its position in shares of Revolution Medicines by 2.9% in the third quarter. Brighton Jones LLC now owns 3,565 shares of the company’s stock valued at $732,000 after acquiring an additional 99 shares in the last quarter. TD Waterhouse Canada Inc. lifted its position in shares of Revolution Medicines by 37.0% in the third quarter. TD Waterhouse Canada Inc. now owns 370 shares of the company’s stock valued at $76,000 after acquiring an additional 100 shares in the last quarter. Finally, Meeder Advisory Services Inc. lifted its position in shares of Revolution Medicines by 3.0% in the first quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock valued at $401,000 after acquiring an additional 120 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

About Revolution Medicines

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers.

The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.